Spinal Stimulation During Exercise in Heart Failure

Sponsor
Mayo Clinic (Other)
Overall Status
Suspended
CT.gov ID
NCT02659202
Collaborator
(none)
40
1
1
103
0.4

Study Details

Study Description

Brief Summary

The purpose of this proposal is to determine whether epidural spinal cord stimulation can modulate cardiovascular control during exercise in Heart Failure patients.

Condition or Disease Intervention/Treatment Phase
  • Device: Precision Spinal Cord Stimulator System
N/A

Detailed Description

Forty Heart Failure (>18 yrs. of age) will be recruited. The study will include a total of 2 visits. All experiments will take place at the Mayo Clinic; at the outpatient radiology for MRI screening, the Charlton Clinical Research Unit (CRU) for surgical suite for spinal cord stimulation placement and the Saint Mary's Hospital Clinical Research Unit for clinical exercise laboratory for the exercise protocol and overnight stay.

Study visit 1 will include eligibility screening, consenting process, completion of a health questionnaire and performance of a peak oxygen consumption (VO2) test. Additionally, subjects will undergo a screening lumbar MRI to ensure that there are no anatomical anomalies in or around the epidural area consistent with standard clinical practice for epidural stimulator lead placement associated with chronic pain syndromes.

Study visit 2 will include an overnight stay in the Saint Mary's Hospital Clinical Research Unit. Patients will check in to the CRU in the morning of day 1, visit 2. Prior to placement of stimulating electrodes an international normalized ratio (INR) will be checked to ensure safe clotting. An anesthesiologist will place the electrodes in the lumbar/thoracic epidural space in a manner that is standard for the clinical placement of temporary electrodes in humans. The participants will then transfer to the clinical exercise laboratory to start the exercise protocol. Participants will rest 15 minutes prior to starting exercise. Exercise will take place on a vertical bike where they will perform a submaximal cycling exercise at 30% of peak work for 29 minutes. Thigh cuffs will be placed on thigh bilaterally and inflated intermittently to pressures of 80m mmHg. After the testing is complete, participants will return to their room in the Clinical Research Unit for the rest of the day and sty over night.

On day two of visit two, participants will repeat the testing from day one with new randomization to determine reliability of testing performed on day one. After the exercise on day two of visit two, the spinal cord stimulator leads and radial arterial catheter will be removed.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Spinal Cord Stimulation to Inhibit Afferent Feedback During Exercise in Heart Failure
Actual Study Start Date :
Jan 1, 2016
Anticipated Primary Completion Date :
Aug 1, 2024
Anticipated Study Completion Date :
Aug 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Precision Spinal Cord Stimulator System

Intervention:the precision system will consist of a pulse generator that will not be implanted, temporary percutaneous leads lead extensions, each packaged as a separate kit.

Device: Precision Spinal Cord Stimulator System
The precision system will consist of a pulse generator that will not be implanted, temporary percutaneous leads, surgical paddle leads and lead extensions, each packaged as a separate kit.

Outcome Measures

Primary Outcome Measures

  1. Mean Arterial Pressure [2 days]

    This will allow for continuous real-time intra-arterial measurement of beat-to-beat blood pressure.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria, includes:
  • Heart Failure patients with reduced ejection fraction:

  • History of ischemic or idiopathic dilated cardiomyopathy (duration > 1yr.) stable for

3mo and New York Heart Association Class I-III

  • Not pacemaker dependent

  • Body Mass Index ≤35

  • Ejection Fraction < 40%

  • Current nonsmokers with < 15 pack year history

  • Able to exercise

Exclusion Criteria includes:
  • History of cardiopulmonary disorders and dangerous arrhythmias

  • Pregnant women

  • Taking prescribed opioid medications or have had a fusion or laminectomy at L3 or above

  • Patients with a recent drug-eluding stent

  • History of spinal stenosis, lumbar radiculopathy, or peripheral neuropathy

  • Must not currently be taking blood thinners or anticoagulant medications.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mayo Clinic in Rochester Rochester Minnesota United States 55905

Sponsors and Collaborators

  • Mayo Clinic

Investigators

  • Principal Investigator: Bruce Johnson, PhD, Mayo Clinic

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Bruce Johnson, PI, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT02659202
Other Study ID Numbers:
  • 14-002521
First Posted:
Jan 20, 2016
Last Update Posted:
Feb 11, 2022
Last Verified:
Feb 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Keywords provided by Bruce Johnson, PI, Mayo Clinic
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 11, 2022